Nanomedicine review: Clinical developments in liposomal applications
E Beltrán-Gracia, A López-Camacho… - Cancer …, 2019 - Springer
Background In recent years, disease treatment has evolved strategies that require increase
in pharmaceutical agent's efficacy and selectivity while decreasing their toxicity in normal …
in pharmaceutical agent's efficacy and selectivity while decreasing their toxicity in normal …
Liposomal drug delivery systems and anticancer drugs
Cancer is a life-threatening disease contributing to~ 3.4 million deaths worldwide. There are
various causes of cancer, such as smoking, being overweight or obese, intake of processed …
various causes of cancer, such as smoking, being overweight or obese, intake of processed …
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012
M Rasche, M Zimmermann, L Borschel, JP Bourquin… - Leukemia, 2018 - nature.com
Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in
recent decades. However, it remained unknown whether advances in first-line treatment …
recent decades. However, it remained unknown whether advances in first-line treatment …
Collaborative efforts driving progress in pediatric acute myeloid leukemia
CM Zwaan, EA Kolb, D Reinhardt… - Journal of clinical …, 2015 - ascopubs.org
Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …
leukemia (AML) have made enormous progress during the past decades. Because AML is a …
Pediatric AML: from biology to clinical management
JDE De Rooij, CM Zwaan… - Journal of clinical …, 2015 - mdpi.com
Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …
[HTML][HTML] Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology …
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce
disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase …
disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase …
Pediatric acute myeloid leukemia—past, present, and future
JCM | Free Full-Text | Pediatric Acute Myeloid Leukemia—Past, Present, and Future Next
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …
Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy
CW Elgarten, R Aplenc - Current Opinion in Pediatrics, 2020 - journals.lww.com
Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A …
RE van Weelderen, K Klein, CJ Harrison… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE A previous study by the International Berlin-Frankfurt-Münster Study Group (I-
BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic …
BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic …
A concise review on cancer treatment methods and delivery systems
The ultimate purpose of current cancer research is to develop a comprehensive treatment for
cancer. Recent studies have shown an increased interest in investigating the capacity of …
cancer. Recent studies have shown an increased interest in investigating the capacity of …